Tradestie Institutional Equity Comparison Engine

LYRA vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LYRA N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -25032.0% vs -485.4% ยท YoY -87.2% vs +408.6%
Momentum & Technical Winner SRZN
1Y -94.3% vs +130.6% ยท 52W Pos 1% vs 69%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% SRZN +130.62% Spread: +183.6 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LYRA Revenue SRZN Revenue LYRA Op. Margin SRZN Op. Margin Margin Edge
FY2021 $0M N/A -15303.5% N/A LYRA
FY2022 $0M $10M -4131.0% -354.7% SRZN
FY2023 $0M N/A -4308.1% N/A LYRA
FY2024 $0M $10M -6280.8% -239.7% SRZN
FY2025 $0M $0M -7794.5% -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (1) vs SRZN (6)
Institutional Metric LYRA SRZN Criterion Row Winner
Market Capitalization Scale $2.3M $602.5M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -87.2% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -25032.0% -485.4% Higher Margin SRZN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -404.5% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 1% ($0โ€“$38) 69% ($12โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 1.28ฮฒ ยท 66% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 33.2 / 100 (SELL) Higher Composite LYRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs SRZN Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.